...
首页> 外文期刊>Journal of neuroinflammation >Cellular localization of kinin B1 receptor in the spinal cord of streptozotocin-diabetic rats with a fluorescent [Nα-Bodipy]-des-Arg9-bradykinin
【24h】

Cellular localization of kinin B1 receptor in the spinal cord of streptozotocin-diabetic rats with a fluorescent [Nα-Bodipy]-des-Arg9-bradykinin

机译:带有荧光[N α -Bodipy] -des-Arg 9 1 受体的细胞定位>-缓激肽

获取原文

摘要

Background The kinin B1 receptor (B1R) is upregulated by pro-inflammatory cytokines, bacterial endotoxins and hyperglycaemia-induced oxidative stress. In animal models of diabetes, it contributes to pain polyneuropathy. This study aims at defining the cellular localization of B1R in thoracic spinal cord of type 1 diabetic rats by confocal microscopy with the use of a fluorescent agonist, [Nα-Bodipy]-des-Arg9-BK (BdABK) and selective antibodies. Methods Diabetes was induced by streptozotocin (STZ; 65 mg/kg, i.p.). Four days post-STZ treatment, B1R expression was confirmed by quantitative real-time PCR and autoradiography. The B1R selectivity of BdABK was determined by assessing its ability to displace B1R [125I]-HPP-desArg10-Hoe140 and B2R [125I]-HPP-Hoe 140 radioligands. The in vivo activity of BdABK was also evaluated on thermal hyperalgesia. Results B1R was increased by 18-fold (mRNA) and 2.7-fold (binding sites) in the thoracic spinal cord of STZ-treated rats when compared to control. BdABK failed to displace the B2R radioligand but displaced the B1R radioligand (IC50 = 5.3 nM). In comparison, IC50 values of B1R selective antagonist R-715 and B1R agonist des-Arg9-BK were 4.3 nM and 19 nM, respectively. Intraperitoneal BdABK and des-Arg9-BK elicited dose-dependent thermal hyperalgesia in STZ-treated rats but not in control rats. The B1R fluorescent agonist was co-localized with immunomarkers of microglia, astrocytes and sensory C fibers in the spinal cord of STZ-treated rats. Conclusion The induction and up-regulation of B1R in glial and sensory cells of the spinal cord in STZ-diabetic rats reinforce the idea that kinin B1R is an important target for drug development in pain processes.
机译:背景激肽B1受体(B1R)被促炎性细胞因子,细菌内毒素和高血糖症引起的氧化应激上调。在糖尿病的动物模型中,它导致疼痛多发性神经病。这项研究旨在通过使用荧光激动剂,[Nα-Bodipy] -des-Arg9-BK(BdABK)和选择性抗体通过共聚焦显微镜确定1型糖尿病大鼠胸脊髓中B1R的细胞定位。方法链脲佐菌素(STZ; 65 mg / kg,腹腔注射)诱导糖尿病。 STZ处理后四天,通过定量实时PCR和放射自显影证实了B1R表达。 BdABK的B1R选择性通过评估其取代B1R [125I] -HPP-desArg10-Hoe140和B2R [125I] -HPP-Hoe 140放射性配体的能力来确定。还对热痛觉过敏评估了BdABK的体内活性。结果与对照组相比,STZ处理的大鼠胸脊髓中的B1R增加了18倍(mRNA)和2.7倍(结合位点)。 BdABK未能置换B2R放射性配体,但置换了B1R放射性配体(IC50 = 5.3 nM)。相比之下,B1R选择性拮抗剂R-715和B1R激动剂des-Arg9-BK的IC50值分别为4.3 nM和19 nM。腹膜内BdABK和des-Arg9-BK在STZ治疗的大鼠中引起剂量依赖性热痛觉过敏,但在对照大鼠中却没有。 B1R荧光激动剂与STZ处理的大鼠脊髓中的小胶质细胞,星形胶质细胞和感觉C纤维的免疫标记共定位。结论STZ糖尿病大鼠脊髓神经胶质细胞和感觉细胞中B1R的诱导和上调增强了激肽B1R是疼痛过程中药物开发的重要靶点的观点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号